drugset / Trial / NCT03717415
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic solid tumors.
Timeline
- Start
- 2019-01-02
- Primary completion
- 2022-05-01
- Completion
- 2022-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Rebastinib | Small molecule | 50 mg | Oral |
| Subject | Rebastinib | Small molecule | 100 mg | Oral |
Indications
No indication recorded.